Shareholder Information

Shares Issued

The number of ordinary shares in issue are 169,117,640.

Major shareholders (as at 31 January 2017)

Shareholders holding more than 3% of the share capital of the Company were:

Shareholder Number of shares held % issued share capital
Harwood Capital* 25,000,000 14.78%
Legal & General Investment Management 24,742,135 14.63%
Schroder Investment Management 14,630,383 8.65%
Fidelity International 10,448,405 6.18%
Aviva Investors 8,404,328 4.97%
Cavendish Asset Management 6,836,445 4.04%
Henderson Global Investors 6,602,092 3.90%
Slater Investments 6,095,978 3.60%
Milton Asset Management 5,551,297 3.28%
Brian George Kennedy 5,398,134 3.19%

Where applicable, shares held are direct and indirect holdings.
* Christopher Mills, who is a non-executive Director of Quantum Pharma Plc, is the Chief Executive of North Atlantic Smaller Companies Investment Trust plc and also Chief Investment Officer of Harwood Capital LLP.

Director Shareholdings

  Shares Held %
Gerard Murray 200,000 0.12
Chris Rigg 162,059 0.10
Dr. John Brown 73,529 0.04
Ian Johnson 58,824 0.03

Shares not in public hands

In terms of AIM Rules published July 2016 and insofar as it is aware, as at 20 February 2017, 29.7% of the Company's AIM securities was not in public hands.

Restrictions in transfer of AIM securities

There are no restrictions on the transfer of securities.

UK City Code on Takeovers and Mergers

Quantum Pharma Plc is subject to the UK City Code on Takeovers and Mergers.

Details of other exchanges or trading platforms

Other than AIM, the Company's shares are not admitted to or traded on any other exchanges or trading platforms.


Page last updated: 20 February 2017

Quantum Pharmaceuticals
UL Medicines
Quantum Aseptics
PERN Consumer Products
Biodose Intelligent Medication Management
Biodose Services